Breast cancers encompass ductal carcinoma in situ, non-metastatic and metastatic breast cancer, and pregnancy-associated breast cancer.

The Breast Cancer Disease Site Group (Breast Cancer DSG) produces evidence-based reports to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances. The titles of the reports produced to date by the Breast Cancer DSG are listed below, together with links to the PDF versions of those reports.

Breast Cancer Staging

• Baseline Staging Tests in Primary Breast Cancer
  1-14 PG: April 2003 Update
  
  • Summary
  • Summary & Full Report

Ductal Carcinoma in Situ

• Management of Ductal Carcinoma In Situ of the Breast
  1-10 Version 2.2006: September 2006 Rewrite
  
  • Practice Guideline
  • Evidence-Based Series

Non-Metastatic Breast Cancer

Locoregional Therapy

• Surgical Management of Early Stage Invasive Breast Cancer
  1-1 PG Version 2.2003: January 2003 Rewrite
  
  • Summary
  • Summary & Full Report
• Breast Irradiation in Women with Early-Stage Invasive Breast Cancer Following Breast Conserving Surgery
  1-2 PG: January 2002 Update
  
  • Summary
  • Summary & Full Report

Systemic Therapy

• Adjuvant Taxane Therapy for Women with Early-Stage Invasive Breast Cancer
  1-7 EBS: December 2006
  
  • Practice Guideline
  • Evidence-Based Series
• Adjuvant Systemic Therapy for Node-Negative Breast Cancer
  1-8 PG May 2003 Update
  
  • Summary
  • Summary & Full Report
• Adjuvant Ovarian Ablation in the Treatment of Premenopausal Women with Early Stage Invasive Breast Cancer
  1-9 EBS July 2010
  
  • Summary
  • Summary & Full Report
    
    
• The Role of Aromatase Inhibitors in Adjuvant Therapy for Postmenopausal Women with Hormone Receptor-Positive Breast Cancer
  1-18 EBS: February 2008 Update
  
  • Practice Guideline
  • Evidence-Based Series
• The Role of Taxanes in Neoadjuvant Chemotherapy for Women with Non-Metastatic Breast Cancer
  1-20 PG: December 2004
  
  • Summary
  • Summary & Full Report
• The Role of Trastuzumab in Adjuvant and Neoadjuvant Therapy in Women with HER2/neu-Overexpressing Breast Cancer
  1-24 EBS: May 2006
  
  • Practice Guideline
  • Evidence-Based Series

Metastatic Breast Cancer

• The Role of the Taxanes in the Management of Metastatic Breast Cancer
  1-3 PG Version 2.2003: April 2003 Rewrite
  
  • Summary
  • Summary & Full Report
• Vinorelbine in Stage IV Breast Cancer
  1-4 ES: November 2003 Update
  
  • Summary
  • Summary & Full Report
• The Role of Aromatase Inhibitors in the Treatment of Postmenopausal Women with Metastatic Breast Cancer
  1-5 PG: October 2003 Update
  
  • Summary
  • Summary & Full Report
• Epirubicin, as a Single Agent or in Combination, for Metastatic Breast Cancer
  1-6 PG: April 2003 Update
  
  • Summary
  • Summary & Full Report
• The Role of Gemcitabine in the Management of Metastatic Breast Cancer
  1-12 EBS: January 2007 Update
  
  • Practice Guideline
  • Evidence-Based Series
• Fulvestrant for Systemic Therapy of Locally Advanced or Metastatic Breast Cancer in Postmenopausal Women
  1-13 EBS: September 2008
  
  • Practice Guideline
  • Evidence-Based Series
• The Role of Trastuzumab (Herceptin) in the Treatment of Women with HER2/neu-Overexpressing Metastatic Breast Cancer
  1-15 PG Version 2.2004: November 2005 Update
  
  • Summary
  • Summary & Full Report
• Capecitabine in Stage IV Breast Cancer
  1-16 PG Version 2.2003: November 2003 Rewrite
  
  • Summary
  • Summary & Full Report

Both Metastatic Breast Cancer and Non-Metastatic Breast Cancer

• Use of Bisphosphonates in Women with Breast Cancer
  1-11 PG Version 2.2002: April 2004 Update
  
  • Summary
  • Summary & Full Report
• The Role of HER2/neu in Systemic and Radiation Therapy for Women with Breast Cancer
  1-17 EBS: November 2006
  
  • Practice Guideline
  • Evidence-Based Series